Impact of protocol change on individual factors related to course of adverse reactions to chemotherapy for breast cancer
- 75 Downloads
Asthenia, myalgia, arthralgia, mucositis, abdominal pain, diarrhea, and neutropenia are adverse reactions commonly reported by women undergoing chemotherapy. Traditional approaches do not take into account the effect that chemotherapeutic changes and variable interactions can cause in adverse reactions. We aimed to identify the impact of the change of a chemotherapy protocol within the same treatment in profiles associated with adverse reactions.
A total of 166 women admitted to the Brazilian National Institute of Cancer (INCA) were followed. Polymorphisms, clinical variables, and FAC-D protocols (3 cycles of cyclophosphamide, 5-fluorouracil, and doxorubicin followed by 3 cycles of docetaxel) composed the set of independent variables analyzed. Reaction levels were recorded at the end of each chemotherapy cycle via interviews. Marginal models were fitted.
The results of marginal models for non-hematological reactions revealed that the docetaxel phase was associated with increased reaction levels compared with the FAC phase. In addition, the set of factors associated with the reactions changed in each protocol. The post-menopausal status was related to high levels of asthenia in docetaxel protocol whereas CYP2B6 polymorphism (rs3745274) was related to high levels in FAC protocol. Regarding the docetaxel phase, high levels of abdominal pain and mucositis were related to CBR3 gene (rs8133052) polymorphism and diabetes respectively.
The results suggest the need for monitoring non-hematological reactions during the docetaxel phase of FAC-D treatment. The factors related to more severe reactions depend on the chemotherapy protocol used.
KeywordsChemotherapy Adverse reactions Longitudinal models Breast cancer Polymorphisms
The authors thank the Instituto Nacional do Cancer (INCA), the Programa de Engenharia Biomédica (Universidade Federal do Rio de Janeiro), and all of the women who participated in this study.
This work was supported by the Conselho Nacional de Pesquisa e Desenvolvimento (CNPQ) and the Fundação Carlos Chagas Filho de Amparo à Pesquisa no Rio de Janeiro (FAPERJ).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The INCA Ethics Research Committee approved the study protocol (number 129/08), and all subjects signed the informed consent form before inclusion in this study.
- 3.Solimando DA (2003). Drug information handbook for oncology: featuring a complete guide to combination chemotherapy regimens. Lexi-compGoogle Scholar
- 4.Chu E, DeVita VT Jr (2017). Physicians' Cancer Chemotherapy Drug Manual 2018. Jones & Bartlett LearningGoogle Scholar
- 7.Menon SZ, Lima AC, Chorilli M, Franco YO (2005) Reações adversas a medicamentos (RAMs). Saúde Rev 7(16):71–79Google Scholar
- 8.Larini L (2009). Fármacos e medicamentos. Artmed EditoraGoogle Scholar
- 13.Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, Abramson VG, Chakravarthy AB, Friedman DL, Cella DF (2013) Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer 119(13):2375–2382. https://doi.org/10.1002/cncr.28016 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5fluorouracil toxicity. Analysis of a large scale phase I trial. Cancer 75:11–17. https://doi.org/10.1002/1097-0142(19950101)75:1<11::AID-CNCR2820750104>3.0.CO;2-N CrossRefPubMedGoogle Scholar
- 17.Zhang BL, Tong S, Zhang BN, Zheng S, Ning LÜ, Xu BH et al (2011) Polymorphisms ofgstp1is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J 124(2):199–204. https://doi.org/10.3760/cma.j.issn.0366-6999.2011.02.008 CrossRefPubMedGoogle Scholar
- 19.RochaV PR, Fernandes JF, Filion A, Bittencourt H, Silva W Jr et al (2009) Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 23(3):545–556. https://doi.org/10.1038/leu.2008.323 CrossRefGoogle Scholar
- 20.Ikeda M, Tsuji D, Yamamoto K, Kim YI, Daimon T, Iwabe Y, Hatori M, Makuta R, Hayashi H, Inoue K, Nakamichi H, Shiokawa M, Itoh K (2015) Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. Drug Metab Pharmacokinet 30(2):149–153. https://doi.org/10.1016/j.dmpk.2014.09.009 CrossRefPubMedGoogle Scholar
- 21.Aguiar ES, Giacomazzi JS, Aishameriane V, Bock H, Saraiva ML, Schuler L, Duarte D, Santos P, Almeida GR, Cale M, Camey SA, Ashton PP (2012) GSTM1, GSTT1, and GSTP1 polymorphisms, breast cancer risk factors and mammographic density in women submitted to breast cancer screening. Rev Bras Epidemiol 15(2):246–255. https://doi.org/10.1590/S1415-790X2012000200002 CrossRefPubMedGoogle Scholar
- 25.Chu E, DeVita VT Jr (2009) Physicians’ cancer chemotherapy drug manual 2018. Jones & Bartlett Learning. https://doi.org/10.3779/j.issn.1009-3419.2009.11.10
- 26.Saad ED, Hoff PM, Carnelós RP, Katz A, Novis YA, Pietrocola M et al (2002) Critérios comuns de toxicidade do Instituto Nacional de Câncer dos Estados Unidos. Rev Bras Cancerol 48(10):63–96Google Scholar
- 28.Diggle P, Diggle PJ, Heagerty P, Heagerty PJ, Liang KY, Zeger S (2002) Analysis of longitudinal data. Oxford University PressGoogle Scholar
- 33.Burstein HJ. (2009). Personalized medicine and breast cancer care. Personalized Medicine and Breast Cancer CareGoogle Scholar
- 34.Seguin C, Kovacevich N, Voutsadakis IA (2017) Docetaxel-associated myalgia–arthralgia syndrome in patients with breast cancer. Breast Cancer: Targets Ther 9:39Google Scholar
- 36.Agresti A, Kateri M (2011) Categorical data analysis. Springer, Berlin Heidelberg, pp 206–208Google Scholar